AbCellera Biologics Inc

15. Sept. 2026, 23:06 UTC

Abcellera Biologics shares declined in after-market trading, reflecting broader market concerns after a drop in the New York Empire State Manufacturing Index.

14. Sept. 2026, 20:08 UTC

Abcellera Biologics is advancing as positive sentiment from Schrödinger's licensing agreement with Tectora Therapeutics influences market activity.

11. Sept. 2026, 23:06 UTC

Abcellera Biologics Inc. shares declined in after-market trading, with no specific company news identified. Broader inflation concerns may be influencing market sentiment.

10. Sept. 2026, 20:07 UTC

Abcellera Biologics Inc shares are lower today, continuing a decline since Wednesday's close. The stock trades significantly below its 20-day moving average.

4. Sept. 2026, 20:08 UTC

Abcellera Biologics Inc shares are lower today amid broader market selling pressure following a strong jobs report, despite earlier gains during the session.

3. Sept. 2026, 23:05 UTC

Abcellera Biologics Inc shares are higher in after-market trading, supported by broader market gains amid easing interest rate hike concerns. No specific company news was identified.

1. Sept. 2026, 20:08 UTC

Abcellera Biologics Inc shares are lower today amid broader market declines and rising oil prices, which have renewed inflation concerns and interest rate hike expectations.

31. Aug. 2026, 23:06 UTC

Abcellera Biologics Inc shares declined in after-market hours, reflecting broader market sentiment influenced by comments on inflation and potential interest rate hikes.

28. Aug. 2026, 23:01 UTC

Abcellera Biologics Inc shares are trading lower in after-market hours. No specific company news was identified to explain this movement.

26. Aug. 2026, 19:56 UTC

Abcellera Biologics Inc shares are lower today, influenced by declines in the ARK Genomic Revolution ETF and broader genomic sector trends.

25. Aug. 2026, 23:06 UTC

Abcellera Biologics Inc. shares declined slightly in after-market trading, despite remaining above their 20-day moving average after recent gains.

24. Aug. 2026, 23:36 UTC

Abcellera Biologics Inc. is rising in after-market trading, fueled by a director's $570,000 insider purchase near its 52-week high, indicating insider confidence.

21. Aug. 2026, 19:36 UTC

Abcellera Biologics Inc shares are lower today amid broader market pressures. The decline coincides with a drop in U.S. Treasury yields and infrastructure-related assets.

20. Aug. 2026, 19:16 UTC

Abcellera shares lower amid broader market pressures, influenced by SPDR ETF.

19. Aug. 2026, 23:02 UTC

Abcellera Biologics Inc shares are higher in after-hours trading, reflecting increased investor interest and social media discussions about the stock's potential at $12.20.

18. Aug. 2026, 19:56 UTC

Abcellera Biologics Inc shares are lower, influenced by declines in small-cap stocks and rising Treasury yields amid ongoing inflation concerns.

17. Aug. 2026, 23:06 UTC

Abcellera Biologics Inc shares are lower in after-market trading, following unusual volatility and a decline in the Russell 2000 Index.

14. Aug. 2026, 19:44 UTC

Abcellera Biologics Inc shares are higher today amid increased call option volume and discussions of insider buying, with the stock trading around $10.50.

13. Aug. 2026, 19:31 UTC

Abcellera Biologics priced an oversubscribed offering at $9.75 per share, aiming to raise $200 million. Shares are higher since Wednesday's close despite earlier pullback.

12. Aug. 2026, 20:02 UTC

Abcellera Biologics has launched a $200 million public offering to support its lead program, while shares are advancing during today's trading session.

11. Aug. 2026, 22:51 UTC

Abcellera Biologics announced a $200 million public offering, contributing to a decline in after-market trading amid investor concerns over potential dilution.

10. Aug. 2026, 23:06 UTC

Abcellera Biologics reported positive Phase 2 trial results for ABCL635, but shares are lower in after-market hours amid broader market declines.

8. Aug. 2026, 00:06 UTC

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are trading higher in after-market hours.

7. Aug. 2026, 23:21 UTC

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are sharply higher in after-market trading amid positive investor sentiment.

6. Aug. 2026, 23:06 UTC

Abcellera Biologics Inc. shares are lower in after-market trading, despite earlier reaching a session high and remaining above the 20-day moving average.

5. Aug. 2026, 23:02 UTC

Abcellera Biologics shares are lower in after-market hours following disappointing Q2 results, with an EPS of -$0.18 and revenue of $4.1 million.

3. Aug. 2026, 19:36 UTC

Abcellera Biologics Inc shares are higher as market sentiment improves following President Trump's cancellation of a military strike on Iran.

31. Juli 2026, 19:33 UTC

Abcellera Biologics Inc is declining during Friday's session, reflecting broader biotech sector weakness amid rising yields and inflation concerns.

30. Juli 2026, 23:41 UTC

Abcellera Biologics shares are lower in after-market trading, reflecting broader market volatility following the Federal Reserve's decision to maintain interest rates.

29. Juli 2026, 23:51 UTC

Abcellera Biologics Inc. shares were roughly flat in after-market hours, with no specific news identified. The stock is down significantly from last month's close.